Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings

[1]  Baosheng Li,et al.  Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions , 2019, Journal of cancer research and therapeutics.

[2]  S. Gettinger,et al.  Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  T. Honjo,et al.  Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model , 2016, Proceedings of the National Academy of Sciences.

[4]  J. Larkin,et al.  Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.

[5]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[8]  A. Ogunniyi,et al.  Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology , 2015, The Annals of pharmacotherapy.

[9]  H. Nakashima,et al.  Immunohistological analysis for immunological response and mechanism of interstitial fibrosis in IgG4-related kidney disease , 2015, Modern rheumatology.

[10]  P. Ott,et al.  PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma , 2015, Oncotarget.

[11]  A. Rudensky,et al.  Continuous requirement for the T cell receptor for regulatory T cell function , 2014, Nature Immunology.

[12]  E. Shevach,et al.  A Self-Reactive TCR Drives the Development of Foxp3+ Regulatory T Cells That Prevent Autoimmune Disease , 2011, The Journal of Immunology.

[13]  R. Colvin,et al.  Kidney transplantation: mechanisms of rejection and acceptance. , 2008, Annual review of pathology.

[14]  Yi-hong Wang,et al.  Cutting Edge: Programed Death (PD) Ligand-1/PD-1 Interaction Is Required for CD8+ T Cell Tolerance to Tissue Antigens1 , 2006, The Journal of Immunology.

[15]  Lieping Chen,et al.  Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. , 2005, Kidney international.

[16]  Wenda Gao,et al.  PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. , 2005, Clinical immunology.

[17]  T. Okazaki,et al.  Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 , 2005, Nature Immunology.

[18]  P. Wahl,et al.  Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[20]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.